|

Neoadjuvant immunochemotherapy Clinical Trials

3 actively recruiting trials

▼ -1 trial since June 2026

Also known as: Neoadjuvant immunotherapy

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • Sun Yat-sen University1
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • Henan Cancer Hospital1

Indications

  • Cancer3
  • Surufatinib1
  • Neoadjuvant Immunochemotherapy1
  • Toripalimab1
  • Neoadjuvant Treatment1

Other3 trials

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Phase 3
Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial
Phase 2
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.